Compare UiPath Inc (PATH) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Tenet Healthcare Corporation — how do they compare? UiPath Inc trades at $13.45 (market cap $6.91B), while Tenet Healthcare Corporation trades at $263.45 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is far larger — about 3× UiPath Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Tenet Healthcare Corporation for 15 Days on average.
| PATH | THC | |
|---|---|---|
Market Cap | $6.91B | $20.98B |
Volume | 34,321,250 | 428,008 |
Sector | Technology | Health |
52-Week High | $19.29 | $280.77 |
52-Week Low | $9.38 | $161.37 |
Typical Hold Time | 139 Days | 15 Days |
Enterprise Value | $5.70B | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.48, up 3.14% today, showing technical bullish momentum despite mixed earnings results. The company demonstrates strong revenue growth from $892M in 2022 to $1.43B in 2025, with improving profit margins turning positive in 2026. Recent partnerships with Snowflake and BDO highlight expansion in AI orchestration capabilities, while analyst sentiment remains cautious with 67% hold ratings.
PATH offers growth potential through enterprise automation leadership and AI integration, but faces execution risks and competitive pressure. The stock trades below consensus price target of $15.13, representing 12% upside, though negative cash flow trends and valuation concerns warrant careful monitoring of quarterly execution against guidance.
Tenet Healthcare (THC) trades at $265.42, up 2.15% today, with a bullish technical signal from moving averages and strong support near $257. The company shows robust fundamentals, including a 53.31% ROE and consistent earnings beats, with Q3 2026 results due October 29. Revenue growth is supported by higher revenue per case despite softer surgical volumes, as noted by Zacks on September 24, 2026.
The outlook is positive, with an 81.25% analyst buy rating and a $283.36 consensus price target implying ~7% upside. Risks include sustainability of capital returns amid growth investments and potential volume pressures, but solid cash flow and valuation metrics like a 10.07 P/E suggest room for appreciation if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
